FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386154158> ?p ?o ?g. }

• W4386154158 endingPage "999" @default.
• W4386154158 startingPage "989" @default.
• W4386154158 abstract "Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbreviated dual antiplatelet therapy duration after percutaneous coronary intervention (PCI). The aim of this study was to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-polymer zotarolimus-eluting stent in patients at high bleeding risk receiving 1 month of dual antiplatelet therapy after PCI.The Bioflow-DAPT Study is an international, randomized, open-label trial conducted at 52 interventional cardiology hospitals in 18 countries from February 24, 2020, through September 20, 2021. Patients with a clinical indication to PCI because of acute or chronic coronary syndrome who fulfilled 1 or more criteria for high bleeding risk were eligible for enrollment. Patients were randomized to receive either biodegradable-polymer sirolimus-eluting stents or durable-polymer, slow-release zotarolimus-eluting stents after successful lesion preparation, followed by 1 month of dual antiplatelet therapy and thereafter single antiplatelet therapy. The primary outcome was the composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year, and was powered for noninferiority, with an absolute margin of 4.1% at 1-sided 5% alpha.A total of 1948 patients at high bleeding risk were randomly assigned (1:1) to receive biodegradable-polymer sirolimus-eluting stents (969 patients) or durable-polymer zotarolimus-eluting stents (979 patients). At 1 year, the primary outcome was observed in 33 of 969 patients (3.6%) in the biodegradable-polymer sirolimus-eluting stent group and in 32 of 979 patients (3.4%) in the durable-polymer zotarolimus-eluting stent group (risk difference, 0.2 percentage points; upper boundary of the 1-sided 95% CI, 1.8; upper boundary of the 1-sided 97.5% CI, 2.1; P<0.0001 for noninferiority for both tests).Among patients at high risk for bleeding who received 1 month of dual antiplatelet therapy after PCI, the use of biodegradable-polymer sirolimus-eluting stents was noninferior to the use of durable-polymer zotarolimus-eluting stents with regard to the composite of death from cardiac causes, myocardial infarction, or stent thrombosis.URL: https://www.gov; Unique identifier: NCT04137510." @default.
• W4386154158 created "2023-08-26" @default.
• W4386154158 creator A5004606355 @default.
• W4386154158 creator A5027984381 @default.
• W4386154158 creator A5029008971 @default.
• W4386154158 creator A5032028897 @default.
• W4386154158 creator A5032240496 @default.
• W4386154158 creator A5041396872 @default.
• W4386154158 creator A5043811212 @default.
• W4386154158 creator A5046304292 @default.
• W4386154158 creator A5053571811 @default.
• W4386154158 creator A5057789819 @default.
• W4386154158 creator A5058267637 @default.
• W4386154158 creator A5059617202 @default.
• W4386154158 creator A5069182559 @default.
• W4386154158 creator A5073186317 @default.
• W4386154158 creator A5081633579 @default.
• W4386154158 creator A5086692319 @default.
• W4386154158 creator A5087550320 @default.
• W4386154158 date "2023-09-26" @default.
• W4386154158 modified "2023-09-29" @default.
• W4386154158 title "Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial" @default.
• W4386154158 cites W1596397105 @default.
• W4386154158 cites W1840021307 @default.
• W4386154158 cites W1921048136 @default.
• W4386154158 cites W1983126671 @default.
• W4386154158 cites W1997760014 @default.
• W4386154158 cites W2049133279 @default.
• W4386154158 cites W2087150869 @default.
• W4386154158 cites W2099207046 @default.
• W4386154158 cites W2122779695 @default.
• W4386154158 cites W2129429230 @default.
• W4386154158 cites W2135491318 @default.
• W4386154158 cites W2161579754 @default.
• W4386154158 cites W2293715975 @default.
• W4386154158 cites W2329082005 @default.
• W4386154158 cites W2593571361 @default.
• W4386154158 cites W2766845216 @default.
• W4386154158 cites W2808265769 @default.
• W4386154158 cites W2888543854 @default.
• W4386154158 cites W2946796958 @default.
• W4386154158 cites W3005734342 @default.
• W4386154158 cites W3085268750 @default.
• W4386154158 cites W3092570019 @default.
• W4386154158 cites W3114774023 @default.
• W4386154158 cites W3193614870 @default.
• W4386154158 cites W3197469057 @default.
• W4386154158 cites W4213179034 @default.
• W4386154158 cites W4293577771 @default.
• W4386154158 cites W4296301569 @default.
• W4386154158 doi "https://doi.org/10.1161/circulationaha.123.065448" @default.
• W4386154158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37624364" @default.
• W4386154158 hasPublicationYear "2023" @default.
• W4386154158 type Work @default.
• W4386154158 citedByCount "0" @default.
• W4386154158 crossrefType "journal-article" @default.
• W4386154158 hasAuthorship W4386154158A5004606355 @default.
• W4386154158 hasAuthorship W4386154158A5027984381 @default.
• W4386154158 hasAuthorship W4386154158A5029008971 @default.
• W4386154158 hasAuthorship W4386154158A5032028897 @default.
• W4386154158 hasAuthorship W4386154158A5032240496 @default.
• W4386154158 hasAuthorship W4386154158A5041396872 @default.
• W4386154158 hasAuthorship W4386154158A5043811212 @default.
• W4386154158 hasAuthorship W4386154158A5046304292 @default.
• W4386154158 hasAuthorship W4386154158A5053571811 @default.
• W4386154158 hasAuthorship W4386154158A5057789819 @default.
• W4386154158 hasAuthorship W4386154158A5058267637 @default.
• W4386154158 hasAuthorship W4386154158A5059617202 @default.
• W4386154158 hasAuthorship W4386154158A5069182559 @default.
• W4386154158 hasAuthorship W4386154158A5073186317 @default.
• W4386154158 hasAuthorship W4386154158A5081633579 @default.
• W4386154158 hasAuthorship W4386154158A5086692319 @default.
• W4386154158 hasAuthorship W4386154158A5087550320 @default.
• W4386154158 hasBestOaLocation W43861541581 @default.
• W4386154158 hasConcept C126322002 @default.
• W4386154158 hasConcept C141071460 @default.
• W4386154158 hasConcept C168563851 @default.
• W4386154158 hasConcept C2777546689 @default.
• W4386154158 hasConcept C2777921159 @default.
• W4386154158 hasConcept C2778583881 @default.
• W4386154158 hasConcept C2780400711 @default.
• W4386154158 hasConcept C2780797203 @default.
• W4386154158 hasConcept C45393284 @default.
• W4386154158 hasConcept C500558357 @default.
• W4386154158 hasConcept C71924100 @default.
• W4386154158 hasConceptScore W4386154158C126322002 @default.
• W4386154158 hasConceptScore W4386154158C141071460 @default.
• W4386154158 hasConceptScore W4386154158C168563851 @default.
• W4386154158 hasConceptScore W4386154158C2777546689 @default.
• W4386154158 hasConceptScore W4386154158C2777921159 @default.
• W4386154158 hasConceptScore W4386154158C2778583881 @default.
• W4386154158 hasConceptScore W4386154158C2780400711 @default.
• W4386154158 hasConceptScore W4386154158C2780797203 @default.
• W4386154158 hasConceptScore W4386154158C45393284 @default.
• W4386154158 hasConceptScore W4386154158C500558357 @default.
• W4386154158 hasConceptScore W4386154158C71924100 @default.
• W4386154158 hasFunder F4320323077 @default.
• W4386154158 hasIssue "13" @default.

• next